RealPatientRealPatient

Tisa-cel shows durable efficacy in patients with
r/r follicular lymphoma after ≥2 lines of prior therapy1-5

Durable responses over 3 years in ELARA with low rates of grade ≥3 ICANS and CRS2,4

Consistent high response rates were seen, even in high-risk patients:2,3,5

  • POD24
  • Bulky disease
  • High FLIPI
  • Heavily pretreated
  • Double refractory

Emerging real-world evidence reinforces durable efficacy seen in ELARA6

  • References: 1. Kymriah [summary of product characteristics]. Nuremberg, Germany: Novartis Pharma GmbH; 2024.
  • 2. Schuster SJ et al. Presented at ASH 2023, Abstract 601.
  • 3. Dreyling M et al. Presented at ASH 2022, Abstract 608.
  • 4. Fowler NH et al. Nat Med. 2022;28(2):325–332.
  • 5. Data on file, ELARA Clinical Study Report, Novartis Pharmaceuticals Corp, March 2023.
  • 6. Ysebaert L et al. Presented at ASH 2023, Abstract 296.